Champions Oncology Inc

CSBRNASDAQ · USD
4.70USD0.00 (+1.19%)
255

Champions Oncology Inc (CSBR) Covered Calls

Champions Oncology Inc trades in the Biotechnology industry with an IV Rank of 78.57%, high versus the past year. CSBR's highest covered call setup is the $5.00 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 4.60% out of the money with 191 days to expiration, a 6.69% return until expiration, and a 12.79% theoretical annualized return. Across the setups shown, annualized returns run from 12.79% to 12.79% at strikes between $5.00 and $5.00, with 191 to 191 days to expiration, as of Nov 11, 2026.

Read more

Running CSBR covered calls helps you generate income from Champions Oncology Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CSBR covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CSBR stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CSBR covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CSBR covered call is worth writing.

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.

2027-05-211915.004.600.104.9032.006.6912.79-2.09+0.7604.80

As of Nov 11, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank78.57% High
  • Market cap (M$)65
  • 52 weeks high-43.44%
  • 52 weeks low2.40%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$12.00
    155.32% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-12-15
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.08
  • EPS growth next 5 years—

As of Nov 13, 2026